| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Tarun Bastiampillai | Q59159898 |
| P2093 | author name string | Jitender Sareen | |
| Matthew Lander | |||
| P2860 | cites work | Catatonia in Alcohol Withdrawal: A Case Report | Q60417976 |
| Further evidence for clozapine as a dopamine D1 receptor agonist | Q71589799 | ||
| Catatonia due to mixed sedative withdrawal | Q73325291 | ||
| Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors? | Q77153208 | ||
| Catatonia following gabapentin withdrawal | Q77352684 | ||
| Clozapine in schizophrenia patients with recurrent catatonia: report of two cases | Q83086900 | ||
| Recurrent clozapine and lorazepam withdrawal psychosis with catatonia | Q83865702 | ||
| Lorazepam withdrawal-induced catatonia | Q84076551 | ||
| Catatonia associated with temazepam withdrawal | Q84849962 | ||
| Zolpidem-related withdrawal catatonia: a case report | Q84928433 | ||
| Clozapine and associated QTc prolongation | Q85068643 | ||
| Catatonic stupor secondary to gamma-hydroxy-butyric acid (GHB)-dependence and -withdrawal syndrome | Q85923260 | ||
| Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy | Q87269204 | ||
| Sudden-Onset Catatonia Following Clozapine Withdrawal: A Case Report | Q88010840 | ||
| Clozapine-withdrawal catatonia | Q95806221 | ||
| A clinical review of the treatment of catatonia | Q21129101 | ||
| Chemical structure and biological activity of the diazepines | Q24542432 | ||
| Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia | Q24646206 | ||
| Catatonia as a presenting feature of alcohol withdrawal: a case report | Q24678425 | ||
| Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response | Q26829016 | ||
| Benzodiazepine withdrawal-induced catatonia | Q28202733 | ||
| Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal | Q28216716 | ||
| Catatonia after benzodiazepine withdrawal | Q28291846 | ||
| The benzodiazepine withdrawal syndrome | Q28306567 | ||
| Catatonic reactions to high-potency neuroleptic drugs | Q28332443 | ||
| Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome? | Q28332694 | ||
| Catatonia under medication with risperidone in a 61-year-old patient | Q28372699 | ||
| Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation | Q30318839 | ||
| The clinical case report: a review of its merits and limitations | Q30486910 | ||
| Hooked on benzodiazepines: GABAA receptor subtypes and addiction | Q33607409 | ||
| Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II | Q33612521 | ||
| Acute effects of ethanol on GABAA and glycine receptor function | Q33687185 | ||
| Catatonia and its treatment | Q33707689 | ||
| Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia | Q33914366 | ||
| Atypical antipsychotics: mechanism of action. | Q33957716 | ||
| Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse | Q33996824 | ||
| Catatonia and alcohol withdrawal: a complex and underestimated syndrome | Q34030408 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Epigenetic GABAergic targets in schizophrenia and bipolar disorder | Q34087810 | ||
| Catatonic syndrome : treatment response to Lorazepam. | Q34231231 | ||
| Clozapine withdrawal-emergent dystonias and dyskinesias: a case series | Q34475139 | ||
| Drug discontinuation effects are part of the pharmacology of a drug | Q35430065 | ||
| From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid | Q35629246 | ||
| "Scared stiff": catatonia as an evolutionary-based fear response | Q35917085 | ||
| The effects of electroconvulsive therapy on GABAergic function in major depressive patients | Q46533122 | ||
| Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? | Q46570370 | ||
| Increased cortical inhibition in persons with schizophrenia treated with clozapine | Q46726964 | ||
| GABA(A) versus GABA(B) in catatonia | Q46857037 | ||
| Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites | Q46919300 | ||
| Clozapine withdrawal catatonia, psychosis and associated neuroleptic malignant syndrome | Q47635757 | ||
| Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors | Q47816157 | ||
| Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia | Q48083478 | ||
| Clozapine upregulates the expression of the vesicular GABA transporter (VGAT) in rat frontal cortex | Q48126033 | ||
| Chronic ethanol intoxication induces differential effects on GABAA and NMDA receptor function in the rat brain | Q48341036 | ||
| Organic catatonia following frontal lobe injury: response to clozapine | Q48458503 | ||
| Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals | Q48513263 | ||
| Motor phenomena in benzodiazepine withdrawal | Q48934197 | ||
| Catatonia: the ultimate response to fear? | Q51246388 | ||
| Catatonia following abrupt stoppage of clozapine. | Q53964235 | ||
| Effectiveness and safety of rapid clozapine titration in schizophrenia. | Q54417865 | ||
| Clozapine Withdrawal_Emergent Dystonias and Dyskinesias | Q56080397 | ||
| ??? | Q64865570 | ||
| Catatonia in psychotic patients: clinical features and treatment response | Q36014138 | ||
| Clozapine responsive catatonia: A series of five cases | Q36917649 | ||
| Takotsubo Cardiomyopathy and Catatonia in the Setting of Benzodiazepine Withdrawal | Q37166287 | ||
| Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis | Q37260903 | ||
| The catatonia syndrome: forgotten but not gone | Q37626343 | ||
| Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review | Q37726344 | ||
| Antipsychotic occupancy of dopamine receptors in schizophrenia | Q37818511 | ||
| Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. a case series and review of the literature*. | Q38166142 | ||
| Vagal intimations for catatonia and electroconvulsive therapy | Q38209703 | ||
| New insights on the antidepressant discontinuation syndrome. | Q38238790 | ||
| Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. | Q38316927 | ||
| Alcohol and Sedative-Hypnotic Withdrawal Catatonia: Two Case Reports, Systematic Literature Review, and Suggestion of a Potential Relationship With Alcohol Withdrawal Delirium | Q38763286 | ||
| Catatonialike symptomatology and withdrawal dyskinesias | Q39120020 | ||
| Rapid relief of catatonia in mood disorder by lorazepam and diazepam | Q39230346 | ||
| Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects | Q39874380 | ||
| Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report | Q40244914 | ||
| Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome | Q40368770 | ||
| Clonazepam withdrawal-induced catatonia | Q40385620 | ||
| Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. | Q40497111 | ||
| Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report | Q40645743 | ||
| Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics | Q40952478 | ||
| Somatic treatment of catatonia | Q41122452 | ||
| A summary of mechanistic hypotheses of gabapentin pharmacology | Q41743616 | ||
| Augmentative asenapine in a recurrent manic catatonic patient with partial response to clozapine. | Q41980040 | ||
| Catatonia in mixed alcohol and benzodiazepine withdrawal | Q41997300 | ||
| Catatonic dilemma in a 33-year-old woman: a discussion | Q42149909 | ||
| Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders | Q42198082 | ||
| Interactions of some anaesthetic, convulsant, and anticonvulsant drugs at GABA-benzodiazepine receptor-ionophore complexes in rat brain synaptosomal membranes | Q42246730 | ||
| Catatonia associated with glutethimide withdrawal | Q42258642 | ||
| Neuroleptic-induced catatonia: case report. | Q42260326 | ||
| Rebound insomnia after abrupt clozapine withdrawal | Q42550857 | ||
| Catatonia associated with lorazepam withdrawal | Q42550864 | ||
| Baclofen-induced catatonia: modification by serotonergic agents | Q42552879 | ||
| Prolonged psychotic relapse after abrupt clozapine withdrawal. | Q42558755 | ||
| Unexpected dystonia while changing from clozapine to risperidone | Q42567887 | ||
| Baclofen-induced catatonia | Q42638253 | ||
| Clozapine withdrawal catatonia or lethal catatonia in a schizoaffective patient with a family history of Parkinson's disease. | Q42746568 | ||
| Clozapine-withdrawal catatonia | Q43001726 | ||
| Catatonia and CPK elevation in neurosyphilis: role of plural pharmacodynamic mechanisms. | Q43004138 | ||
| Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine | Q43293455 | ||
| Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture | Q43504114 | ||
| Catatonia Associated With Alprazolam Discontinuation in a Young Man With Cardiac Cirrhosis | Q43753612 | ||
| Lorazepam withdrawal catatonia: a case report | Q43942759 | ||
| Increased cortical GABA concentrations in depressed patients receiving ECT. | Q44336422 | ||
| Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report | Q45189024 | ||
| Catatonia recognition and treatment. | Q45915468 | ||
| The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia | Q46297509 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | withdrawal symptom | Q4420149 |
| P304 | page(s) | 139 | |
| P577 | publication date | 2018-07-31 | |
| P1433 | published in | Translational Psychiatry | Q15716636 |
| P1476 | title | Review of withdrawal catatonia: what does this reveal about clozapine? | |
| P478 | volume | 8 |
| Q64260521 | A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder |
| Q96577055 | All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders |
| Q90641392 | Catatonia due to alprazolam withdrawal |
| Q64882655 | Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis. |
| Q89804908 | Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database |
| Q99728086 | GABAB receptor, clozapine, and catatonia-a complex triad |
| Q92134303 | Lorazepam-Resistant Catatonia in an Antipsychotic-Naïve 24-Year-Old with Psychotic Symptoms |
| Q99609521 | Mirtazapine Creating "Miracles" in Psychotic Depression With Catatonia |
Search more.